Ado-tratuzumab emtansine beyond breast cancer: therapeutic role of targeting other HER2-positive cancers

Ado-trastuzumab emtansine (T-DM1) is an antibody–drug conjugate approved by the FDA in 2013 for advanced HER2-positive breast cancer treatment exhibiting promising clinical benefits. However, HER2 overexpression and gene amplification have also been reported in other cancers like gastric cancer, non...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Yang Zheng, Jiayu Zou, Chen Sun, Fu Peng, Cheng Peng
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Frontiers Media S.A. 2023-05-01
coleção:	Frontiers in Molecular Biosciences
Assuntos:	T-DM1 HER2+ cancer therapeutic potential targeted therapy
Acesso em linha:	https://www.frontiersin.org/articles/10.3389/fmolb.2023.1165781/full
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!